What are targeted therapies and when can they be used in the treatment of acute myeloid leukemia?

During the EHA 2022 Congress, Know AML spoke with Jordi Esteve, Hospital Clínic de Barcelona, Barcelona, ES. We asked, What are targeted therapies and when can they be used in the treatment of acute myeloid leukemia?

Esteve begins by explaining what targeted molecules are, and what these agents can achieve, including their clinical benefits compared to other therapies. Esteve discusses venetoclax, new therapeutic combinations, and molecular targets being explored in clinical trials to address unmet needs in the acute myeloid leukemia field.